Myeloid-Derived Suppressor Cells: Cancer, Autoimmune Diseases, and More

Posted by

Oncotarget

Oncotarget published this review in Volume 13, entitled, Myeloid-derived suppressor cells: Cancer, autoimmune diseases, and more" by researchers from Department of Comprehensive Cancer Treatment and Research at Aizu, Fukushima Medical University, Fukushima, Japan; Department of Surgery, Cancer Treatment Center, Aizu Chuo Hospital, Fukushima, Japan; Department of Gastrointestinal Tract Surgery, Fukushima Medical University, Fukushima, Japan; Aizu Oncology Consortium, Fukushima, Japan; Department of Surgery, Nippon Medical School, Tokyo, Japan; Department of Surgery, Bange Kousei General Hospital, Fukushima, Japan; Department of Obstetrics and Gynecology, Fukushima Medical University, Fukushima, Japan; Department of Breast Surgery, Fukushima Medical University, Fukushima, Japan; Department of Chest Surgery, Fukushima Medical University, Fukushima, Japan; Department of Radiation Oncology, Fukushima Medical University, Fukushima, Japan; Department of Colorectoanal Surgery, Aizu Medical Center, Fukushima Medical University, Fukushima, Japan; Fukushima Medical University, Fukushima, Japan. DOI - https://doi.org/10.18632/oncotarget.28303 Correspondence to - Masahiko Shibata - mshibata@fmu.ac.jp Abstract Although cancer immunotherapy using immune checkpoint inhibitors (ICIs) has been recognized as one of the major treatment modalities for malignant diseases, the clinical outcome is not uniform in all cancer patients. Myeloid-derived suppressor cells (MDSCs) represent a heterogeneous population of immature myeloid cells that possess various strong immunosuppressive activities involving multiple immunocompetent cells that are significantly accumulated in patients who did not respond well to cancer immunotherapies. We reviewed the perspective of MDSCs with emerging evidence in this review. Many studies on MDSCs were performed in malignant diseases. Substantial studies on the participation of MDSCs on non-malignant diseases such as chronic infection and autoimmune diseases, and physiological roles in obesity, aging, pregnancy and neonates have yet to be reported. With the growing understanding of the roles of MDSCs, variable therapeutic strategies and agents targeting MDSCs are being investigated, some of which have been used in clinical trials. More studies are required in order to develop more effective strategies against MDSCs. Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28303 Keywords - MDSC, immunosuppression, Treg, TAM, cancer About Oncotarget Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form, and then quickly released to Pubmed. On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/OncotargetYouTube LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957